Cara Therapeutics Garners $12,300,000 Series C Round

  • Feed Type
  • Date
  • Company Name
    Cara Therapeutics
  • Mailing Address
    One Parrott Drive Shelton, CT 06484
  • Company Description
    Cara Therapeutics is an emerging biotechnology company focused on developing novel therapeutics to treat human diseases associated with pain and inflammation. Cara possesses both near-term clinical development opportunities combined with proprietary approaches to developing first-in-class novel therapeutics. Cara’s first patented compound, CR665, has entered clinical testing for acute pain. This best-in-class compound possesses unique analgesic and anti-inflammatory activities appropriate for multiple therapeutic applications. In addition, Cara aims to develop a future pipeline of first-in-class molecules at novel analgesic and anti-inflammatory targets using its proprietary drug screening technology.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series C
  • Proceeds Purposes
    The additional funds will be used primarily for further clinical development of both intravenous and oral formulations of Cara’s second generation peripherally-selective kappa opioid agonist, CR845.
  • M&A Terms
  • Venture Investor
    Devon Park Bioventures
  • Venture Investor
    Ascent Venture Partners
  • Venture Investor
    Mitsubishi Corporation
  • Venture Investor
    Scottish Widows Investment Partnership
  • Venture Investor
    MVM Life Science Partners
  • Venture Investor
    Alta Partners

Trending on Xconomy